Enterprise Therapeutics strengthens leadership team, appoints Amit D. Munshi as Non-Executive Chairman

Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering with respiratory disease, today announced the appointment of Amit D. Munshi as Non-Executive Chairman of the Board of Directors. Amit’s appointment is significant for Enterprise, strengthening the ability of the leadership team as it transitions to a clinical stage development company, addressing areas of critical unmet needs in respiratory disease.

Mr. Munshi has more than 28 years of global biopharmaceutical industry experience in executive management, business development, product development and portfolio management, and has served on several private and public company boards. He is Director, President and Chief Executive Officer of Arena Pharmaceuticals, Inc., a Nasdaq-listed biopharmaceutical company which has a proprietary pipeline in mid-late stage clinical development. Previously, Mr. Munshi served as President and Chief Executive Officer of Epirus Biopharmaceuticals, Inc. and Percivia LLC. Prior to Epirus and Percivia, he was a co-founder and Chief Business Officer of Kythera Biopharmaceuticals, Inc., and held multiple leadership positions at Amgen, Inc. Mr. Munshi holds a B.S. in Economics and a B.A. in History from the University of California, Riverside, and an M.B.A. from the Peter F. Drucker School of Management at Claremont Graduate University.

Dr John Ford, CEO, Enterprise Therapeutics, said: "We are delighted that Amit has chosen to join as Chairman at this exciting time for the Company, as we prepare to take our two lead programmes into the clinic in the next 12 months. Amit brings a wealth of experience in product development, portfolio management and commercial strategy in both the US and EU that will be critical in driving the Company through the next phase of its development."

Amit D. Munshi, Chairman, Enterprise Therapeutics, said: "Enterprise is led by an impressive management team with significant expertise and experience, and is backed by a high-profile syndicate of investors. I believe the Company and its therapeutic programmes have real potential to make a difference to the lives of respiratory disease patients."

Enterprise Therapeutics is developing novel disease-modifying therapies which target underlying mechanisms of mucus congestion, enhancing the clearance of mucus from the airways, thereby restoring lung function and reducing morbidity and mortality in respiratory diseases. Enterprise’s programmes differentiate from the current standard of care as they aim to deliver disease-modifying, clinically effective candidates for a significant number of patients with respiratory diseases, including all CF patients, regardless of underlying mutations, and a large percentage of patients with COPD and severe asthma.

In April 2018 Enterprise closed an oversubscribed £29 million ($41 million USD) Series B round co-led by Versant Ventures and Novartis Venture Fund. The syndicate also included new investor Forbion, founding investor Epidarex Capital and existing investor IP Group.

Register as Visitor to CPhI China 2019!

-----------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.